Skip to content
  • Saturday, 12 September 2026
  • 6:38 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
Pharmaceutical R&D

MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry

Teuku Ryan Mar 25, 2026 0

In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…

Read More
Pharmaceutical R&D

Earendil Labs Secures $787 Million to Accelerate AI-Driven Drug Discovery and Expand Robust Pipeline

Teuku Ryan Mar 23, 2026 0

Earendil Labs, a burgeoning biotechnology firm at the forefront of artificial intelligence (AI)-powered drug discovery, has announced a significant financial…

Read More
Pharmaceutical R&D

Congruence secures $39.5m to advance small molecule correctors pipeline

Teuku Ryan Mar 21, 2026 0

Congruence Therapeutics, a pioneering biotechnology company focused on developing novel small molecule correctors, has successfully closed a significant $39.5 million…

Read More
Pharmaceutical R&D

Excalipoint Therapeutics Launches with $68.7 Million Seed Funding to Advance Novel T-Cell Engager Pipeline

Teuku Ryan Mar 18, 2026 0

Chinese biotech startup Excalipoint Therapeutics has officially launched with a substantial $68.7 million in seed funding, positioning itself to accelerate…

Read More
Data Science & Bioinformatics

Python Decorators Revolutionize Data Pipeline Performance and Reliability for Data Science and Machine Learning

Evan Lee Salim Mar 14, 2026 0

The escalating demands of modern data science and machine learning projects necessitate data pipelines that are not only efficient but…

Read More

Posts pagination

1 … 3 4
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply ChainLungs Revealed as Major Site of Blood Production in Humans Challenging Decades of Medical OrthodoxyTWiV 1286: Clinical Update with Dr. Daniel GriffinUC Davis Health Study Reveals Significant Choline Deficiencies in the Brains of Individuals with Anxiety Disorders
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
The oral exposure challenge in PROTACs: What drug developers need to solve earlyAttention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Sep 12, 2026
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ